CXC Ligand 13 Orchestrates an Immunoactive Microenvironment and Enhances Immunotherapy Response in Head and Neck Squamous Cell Carcinoma

Overview

Journal Int J Immunopathol Pharmacol

Publisher Sage Publications

Specialties Allergy & Immunology
Pathology
Pharmacology

Date 2024 Jan 22

PMID 38252495

Authors

Xiaohu Lin

Xiaomei Zhao

Yiming Chen

Rong Yang

Zhenlin Dai

Wei Li

Chengzhong Lin

Wei Cao

Affiliations

Soon will be listed here.

Abstract

: This study aims to systematically explore the role of chemokine CXC ligand 13 (CXCL13) in head and neck squamous cell carcinoma (HNSCC). : The Genotype-Tissue Expression (GTEx) and The Cancer Genome Atlas (TCGA) databases provided the RNA-seq data for cancer and normal tissues, respectively. Gene set enrichment analysis was applied to search the cancer hallmarks associated with CXCL13 expression. TIMER2.0 was the main platform used to investigate the immune cell infiltration related to CXCL13. Immunohistochemistry was applied to explore the relationship between CXCL13 and patients' prognosis and the relationship between CXCL13 and tertiary lymphoid structures (TLSs). : The expression of CXCL13 was upregulated in most tumors, including HNSCC. The higher expression of CXCL13 was closely related to the positive prognosis of HNSCC. CXCL13 was mainly expressed in B cells and CD8 + T cells, revealing the relationship between its expression and immune activation in the tumor microenvironment. Furthermore, immunohistochemistry and multiple fluorescence staining analysis of HNSCC samples showed a powerful correlation between CXCL13 expression, TLSs formation, and positive prognosis. Finally, CXCL13 significantly increased the response to cancer immunotherapy. : CXCL13 may function as a potential biomarker for predicting prognosis and immunotherapy response and associate with TLSs in HNSCC.

Citing Articles

From heterogeneity to prognosis: understanding the complexity of tertiary lymphoid structures in tumors.

Wang Y, Zhang D, Huang X, Wu G, Wang C, Li J Mol Biol Rep. 2025; 52(1):197.

PMID: 39903372 DOI: 10.1007/s11033-025-10319-3.

B cells and tertiary lymphoid structures in tumors: immunity cycle, clinical impact, and therapeutic applications.

Wu X, Huang Q, Chen X, Zhang B, Liang J, Zhang B Theranostics. 2025; 15(2):605-631.

PMID: 39744696 PMC: 11671382. DOI: 10.7150/thno.105423.

References

Bule P, Aguiar S, Aires-da-Silva F, Dias J . Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy. Int J Mol Sci. 2021; 22(18). PMC: 8464715. DOI: 10.3390/ijms22189804. View

Wang Y, Yu L, Hu Z, Fang Y, Shen Y, Song M . Regulation of CCL2 by EZH2 affects tumor-associated macrophages polarization and infiltration in breast cancer. Cell Death Dis. 2022; 13(8):748. PMC: 9424193. DOI: 10.1038/s41419-022-05169-x. View

Lopez-Bujanda Z, Haffner M, Chaimowitz M, Chowdhury N, Venturini N, Patel R . Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression. Nat Cancer. 2022; 2(8):803-818. PMC: 9169571. DOI: 10.1038/s43018-021-00227-3. View

Jin L, Guo Y, Mao W, Wang J, Jin L, Liu X . Total glucosides of paeony inhibit breast cancer growth by inhibiting TAMs infiltration through NF-κB/CCL2 signaling. Phytomedicine. 2022; 104:154307. DOI: 10.1016/j.phymed.2022.154307. View

Zhang Z, Zhu Y, Wang Z, Zhang T, Wu P, Huang J . Yin-yang effect of tumor infiltrating B cells in breast cancer: From mechanism to immunotherapy. Cancer Lett. 2017; 393:1-7. DOI: 10.1016/j.canlet.2017.02.008. View

Sun D, Wang J, Han Y, Dong X, Ge J, Zheng R . TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic Acids Res. 2020; 49(D1):D1420-D1430. PMC: 7778907. DOI: 10.1093/nar/gkaa1020. View

Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S . Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020; 577(7791):561-565. DOI: 10.1038/s41586-019-1914-8. View

Lin C, Cao W, Ren Z, Tang Y, Zhang C, Yang R . GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC. Oncoimmunology. 2017; 6(11):e1353860. PMC: 5674951. DOI: 10.1080/2162402X.2017.1353860. View

Fridman W, Siberil S, Pupier G, Soussan S, Sautes-Fridman C . Activation of B cells in Tertiary Lymphoid Structures in cancer: Anti-tumor or anti-self?. Semin Immunol. 2022; 65:101703. DOI: 10.1016/j.smim.2022.101703. View

10.

Bery A, Shepherd H, Li W, Krupnick A, Gelman A, Kreisel D . Role of tertiary lymphoid organs in the regulation of immune responses in the periphery. Cell Mol Life Sci. 2022; 79(7):359. PMC: 9188279. DOI: 10.1007/s00018-022-04388-x. View

11.

Liu Q, Song J, Pan Y, Shi D, Yang C, Wang S . Wnt5a/CaMKII/ERK/CCL2 axis is required for tumor-associated macrophages to promote colorectal cancer progression. Int J Biol Sci. 2020; 16(6):1023-1034. PMC: 7053330. DOI: 10.7150/ijbs.40535. View

12.

Cheng Q, Duan W, He S, Li C, Cao H, Liu K . Multi-Omics Data Integration Analysis of an Immune-Related Gene Signature in LGG Patients With Epilepsy. Front Cell Dev Biol. 2021; 9:686909. PMC: 8322853. DOI: 10.3389/fcell.2021.686909. View

13.

Wu T, Yang W, Sun A, Wei Z, Lin Q . The Role of CXC Chemokines in Cancer Progression. Cancers (Basel). 2023; 15(1). PMC: 9818145. DOI: 10.3390/cancers15010167. View

14.

Israr M, DeVoti J, Papayannakos C, Bonagura V . Role of chemokines in HPV-induced cancers. Semin Cancer Biol. 2022; 87:170-183. DOI: 10.1016/j.semcancer.2022.11.010. View

15.

Fasano M, DOnofrio I, Belfiore M, Angrisani A, Caliendo V, Della Corte C . Head and Neck Squamous Cell Carcinoma in Elderly Patients: Role of Radiotherapy and Chemotherapy. Cancers (Basel). 2022; 14(3). PMC: 8833743. DOI: 10.3390/cancers14030472. View

16.

Denton A, Innocentin S, Carr E, Bradford B, Lafouresse F, Mabbott N . Type I interferon induces CXCL13 to support ectopic germinal center formation. J Exp Med. 2019; 216(3):621-637. PMC: 6400543. DOI: 10.1084/jem.20181216. View

17.

Gao S, Liu S, Wang G, Zhou G . CXCL13 in Cancer and Other Diseases: Biological Functions, Clinical Significance, and Therapeutic Opportunities. Life (Basel). 2021; 11(12). PMC: 8708574. DOI: 10.3390/life11121282. View

18.

Tokunaga R, Zhang W, Naseem M, Puccini A, Berger M, Soni S . CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev. 2017; 63:40-47. PMC: 5801162. DOI: 10.1016/j.ctrv.2017.11.007. View

19.

Chakraborty R, Darido C, Liu F, Maselko M, Ranganathan S . Head and Neck Cancer Immunotherapy: Molecular Biological Aspects of Preclinical and Clinical Research. Cancers (Basel). 2023; 15(3). PMC: 9913716. DOI: 10.3390/cancers15030852. View

20.

Sanchez-Magraner L, Gumuzio J, Miles J, Quimi N, Del Prado P, Abad-Villar M . Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer. J Clin Oncol. 2023; 41(14):2561-2570. PMC: 10414696. DOI: 10.1200/JCO.22.01748. View